Multiple myeloma is the second most common hematologic malignancy. In Multiple myeloma a serum or urine monoclonal component is produced by bone marrow plasma cells. Great progresses have been made in the latest 10 years and survivals are nearly doubled. This improvement has been reached with novel efficacious drugs and with implemented diagnostic tools. The diagnosis is made by serum and urine biochemicals exams, by radiological examination and by marrow analysis. Novel diagnostic parameters have been introduced and novel prognosticators are present. Cytogenetics , flow cytometry, PET-CT are only few of them. Laboratory tools are present that can diagnose, detect and monitor disease during follow up. In this presentation an overview of multiple myeloma diagnostic and therapeutic tools will be given according to recent IMWG recommendations and with practical clinical cases discussed.
HbA1c is routinely used in the clinical laboratory to diagnose and monitor diabetes mellitus. Many methods have been standardized to provide precise and accurate results for normal patients. For the other common Hb variants, most of the methods are now relatively free of analytical interference.